Most Recent
Pathology services provider Australian Clinical Labs has been hit with a class over a 2022 data breach that compromised the sensitive personal information of 223,000 customers of its Medlab business, including tests for fertility and STDs.
Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.
A judge hearing a class action against J&J over allegedly ineffective cold medications has questioned the merits of soft class closure in large consumer cases where participation is likely be low, just days after another judge raised similar concerns in a case against Toyota.
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
Saying swear words are now part of the common vernacular, IP Australia has cleared a vitamin company's foul- mouthed trademark for registration, on the proviso that the branding is restricted to goods aimed at adults.
Bupa has hit back at a class action alleging it provided poor quality care to residents at its aged care facilities, saying it was "not appropriate" to run the case as a group proceeding.
A class action against Allergan over recalled breast implants has asked a court to slash parts of the US pharma company’s defence, saying they are "incoherent".
The Full Court has rejected Medibank's bid to appeal a finding that legal professional privilege did not attach to a Deloitte report commissioned in the wake of a massive data breach.
A judge has refused to disqualify himself from case managing Mayne Pharma's latest dispute with US drug maker Cosette over the collapse of their $672 million merger agreement, calling the bid “plainly premature”.